Evidence map›Paper›PMID 40322303›Full record

ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2025

C-reactive Protein Levels in Prediction of the Development or the Progression of Agerelated Macular Degeneration in Patients Examined at Tuzla Canton.

Alma Cickusic, Suzana Pavljasevic, Vahid Jusufovic, Sanja Sefic-Kasumovic, Adisa Pilavdzic Hasic, Meliha Halilbasic

Abstract read
In one paragraph

Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alma CickusicClinic for Eye Diseases, University Clinical Centre Tuzla; Tuzla, Bosnia and Herzegovina.
Suzana PavljasevicPolyclinic for Eye Disease, Health Centre, Tuzla; Tuzla, Bosnia and Herzegovina.
Vahid JusufovicClinic for Eye Diseases, University Clinical Centre Tuzla; Tuzla, Bosnia and Herzegovina.
Sanja Sefic-KasumovicOphthalmology Department "Dr.Sefic" Sarajevo; Sarajevo, Bosnia and Herzegovina.
Adisa Pilavdzic HasicClinic for Eye Diseases, University Clinical Centre Tuzla; Tuzla, Bosnia and Herzegovina.
Meliha HalilbasicClinic for Eye Diseases, University Clinical Centre Tuzla; Tuzla, Bosnia and Herzegovina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Age-related macular degeneration (ARMD) is a chronic, incurable, progressive, multifactorial, neurodegenerative disease, which is one of the leading causes of visual impairment, among individuals above 60 years of age in developed countries. Over the past decades, the role of inflammation and CRP in the pathogenesis of ARMD has been investigated. Objective: The study aimed to investigate the association between inflammation or CRP levels in prediction the development or the progression of ARMD. Methods: This retrospective-prospective, case-control study, was conducted at the Clinic for Eye Diseases, University Clinical Center Tuzla, from 2020. to 2024. Two group of participants were included in this study. The first group (n=100 patients) consisted of patients diagnosed with different stages of ARMD, and second, control group (n=100 patients) consisted of patients without ARMD. The study included subjects of both sexes, divided into three age categories (≤55; 56-66; ≥67 years). Detailed ocular and systemic evaluations were performed, including fundus examination and OCT angiography. A 5mL sample of venous blood was colected to determine serum CRP levels, for the both group of patients, using latex immunoassay method. Statistical analysis, including Student's t-test, Chi square test and posthoc (Turkey) tests, was conducted using SPSS 26 for Windows, with p<0,05 considered significant. Results: Out of 100 patients, 34 were having early, 18 intermediate and 48 were having advanced stages of ARMD. The mean serum CRP levels in the ARMD group (8.39±27.22mg/L) were significantly higher compared to the control group, (2.52±5.35mg/L), p=0,000. Also, serum CRP values by age category, between ARMD subjects and the control group, showed statistically significant differences in all age groups: ≤55 p=0.032; 56-66 p=0.019; ≥67 p=0.000. The mean serum CRP levels was 6.6±6.9 mg/L, 10±13.3 mg/L and 16±22.7 mg/L, in early, intermediate and advanced ARMD, respectively. Comparing these CRP values and different stages of ARMD, there were found statistically significant differences between the three stages. Furthermore, these results showed that mean CRP values increase with disease severity. Conclusion: Based on the obtained results serum CRP levels are significant risk factor in predicting the development and the progression of ARMD. Also, these results emphasize the role of systemic inflammation in the development and progression of ARMD.

Indexed as

C-Reactive ProteinMacular DegenerationAgedBiomarkersBosnia and HerzegovinaCase-Control StudiesDisease ProgressionFemaleHumansInflammationMaleMiddle AgedProspective StudiesRetrospective StudiesBiomarkersC-Reactive Proteinage-related macular degenerationC-reactive proteininflammation

Identifiers

PMID40322303
PMCPMC12045587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.